International Society for Stem Cell Research recently released Best Practices for the Development of Pluripotent Stem Cell-Derived Cellular Therapies. The comprehensive, interactive document is designed for academic and industry scientists and regulators to address critical areas of the translational pipeline and key decision points essential for successful translation to a licensed therapy. BlueRocker Mark Tomishima is a member of a working group that contributed to this publication. Access the resource and learn more: https://lnkd.in/e4dSVffy
BlueRock Therapeutics
Biotechnology Research
Cambridge, Massachusetts 76,494 followers
Striving to transform the treatment of disease by harnessing the power of cell therapy
About us
BlueRock Therapeutics is a clinical stage cell therapy company focused on creating cellular medicines to treat devastating diseases. We are harnessing the power of cell therapy to create a pipeline of new medicines for people suffering from neurological and ophthalmic diseases. Two of our novel investigational cell therapies, one for the treatment of Parkinson’s disease and one for the treatment of primary photoreceptor diseases, are clinical stage programs. BlueRock was founded in 2016 as a joint venture of Versant Ventures and Leaps by Bayer, the impact investing arm of Bayer AG that invests in paradigm-shifting breakthrough innovation. In late 2019, BlueRock became a wholly owned, independently operated subsidiary of Bayer AG. Our culture is defined by the courage to persist regardless of the challenge, the urgency to transform medicine and deliver hope, integrity guided by mission, and community-mindedness with the understanding that we are all part of something bigger than ourselves. For more information, visit www.bluerocktx.com.
- Website
-
http://www.bluerocktx.com
External link for BlueRock Therapeutics
- Industry
- Biotechnology Research
- Company size
- 201-500 employees
- Headquarters
- Cambridge, Massachusetts
- Type
- Privately Held
- Founded
- 2016
- Specialties
- Stem Cell Therapeutics, Engineered Cell Therapy, Cardiology, Neurology, Immunology, Regenerative Medicine, and Cell+Gene
Locations
-
Primary
Get directions
238 Main St
Cambridge, Massachusetts 02142, US
-
Get directions
661 University Ave
Toronto, Ontario, CA
-
Get directions
430 E 29th St
New York, 10016, US
-
Get directions
Müllerstraße 178
Berlin, BE 13353, DE
Employees at BlueRock Therapeutics
Updates
-
NOTICE: It has come to our attention that there have been several fake job listings, offers, and other communications being sent unsolicited to individuals under the alias of BlueRock Therapeutics and members of our talent acquisition team. Included in these communications is a request for personal and banking information. Please do not engage with these communications. They are not legitimate. Any communication from a legitimate BlueRock employee would contain the domain bluerocktx.com.
-
-
Last week, our New York team participated in the 3rd annual Life Science Cares New York Day. Life Science Cares Day invites high school students to explore the world of life sciences through hands-on activities, lab tours, and career conversations. Designed to ignite curiosity and foster a sense of belonging, the event focuses on students who have historically not had access to STEM fields. We enjoyed hosting students in the office and lab, and conducting an experiment! #Community #STEM #FutureScientists
-
-
-
-
-
+1
-
-
Rounding out our Boston-based advocacy events for 2025, BlueRock joined Kizik as National Sponsors for Parkinson's Foundation Moving Day walks. Another great event in our ongoing partnership with Parkinson's Foundation! #ParkinsonsDisease #MovingDay25
-
-
Foundation Fighting Blindness had a beautiful day last Saturday for VisionWalk 2025! Team BlueRock was out representing and had a great time. #Ophthalmology #VisionLoss #Community
-
-
World Sight Day, observed annually on the second Thursday of October, is a global event meant to draw attention to blindness and vision impairment. It was originally initiated by the SightFirstCampaign of Lions Clubs International Foundation in 2000 and has since be adopted by IABP and WHO. #BlueRockers are partnering with Lions Club International for the 2nd year to run a glasses drive across all of our locations. #Ophthalmology #Community
-
-
Join BlueRockers in Boston Saturday, October 11th for the Foundation Fighting Blindness (FFB) 2025 VisionWalk. BlueRock is proud to partner with FFB on a broad range of advocacy and education initiatives including the VisionWalk. Learn more and register at: https://lnkd.in/e-j5wGQv
-
It's Day 2 of the Alliance for Regenerative Medicine’s 2025 Cell & Gene Meeting on the Mesa. BlueRock CEO Seth Ettenberg will be on a panel discussion sponsored by our collaborators FUJIFILM Cellular Dynamics, Inc speaking to lessons learned in the the advancement of iPSC-derived therapies. Should be a great discussion! Check out today’s full lineup of speakers and presentations: www.meetingonthemesa.com #CGMesa25
-
-
Together with Bayer | Pharmaceuticals, BlueRock announced positive 36-month data from our Phase I clinical trial for our investigational cell therapy for the treatment of Parkinson's disease. The data were presented on yesterday at the International Congress of Parkinson’s Disease and Movements Disorders. Read the full release: https://lnkd.in/eEqQiQQ4
-
-
Congrats to our CEO Seth Ettenberg for being elected to the Alliance for Regenerative Medicine 2026 Board of Directors! Such an incredible group of leaders in #RegenerativeMedicine. #Leaders #Innovation
ARM has kicked off this year’s Meeting on the Mesa with a big announcement! At the conference's opening, we officially elected our 2026 Board of Directors. Congratulations to these distinguished individuals who will be key to ARM’s sector leadership this year. Read the release: https://lnkd.in/eHDZYUJB A warm welcome to our new board members: Allyson Berent, DVM – Chief Scientific Officer, Foundation for Angelman Syndrome Therapeutics; Chief Development Officer, Mahzi Therapeutics Warner Biddle – Chief Executive Officer, Kyverna Therapeutics Seth Ettenberg, Ph.D. – President and Chief Executive Officer, BlueRock Therapeutics Jason C. Foster, MBA – Chief Executive Officer, Ori Biotech Lynelle Hoch – President, Cell Therapy Organization, Bristol Myers Squibb Rachel McMinn, Ph.D. – Founder and Chief Executive Officer, Neurogene Inc. Joanne Smith-Farrell, Ph.D. – Chief Executive Officer, Be Biopharma #CGMesa25
-